Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Japan approves Sanofi’s Sarclisa combo for MM treatment

Summary by Pharmaceutical Business Review
The approval follows a positive finding in the pivotal IRAKLIA Phase III study, which demonstrated non-inferior efficacy and pharmacokinetics compared with the intravenous (IV) formulation. It also marks The post Japan approves Sanofi’s Sarclisa combo for MM treatment appeared first on Pharmaceutical Business review.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

Verdict HospitalVerdict Hospital
Reposted by
Pharmaceutical Business reviewPharmaceutical Business review

Japan approves Sanofi’s Sarclisa combo for MM treatment

Sanofi has received approval from Japan's Ministry of Health, Labour and Welfare for its SC formulation of Sarclisa in combination with standard therapies to treat multiple myeloma.The post Japan approves Sanofi’s Sarclisa combo for MM treatment appeared first on Hospital Management.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Verdict Hospital broke the news on Monday, June 22, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Japan icon

Japan

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal